Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors

Introduction: A high proportion of metastatic melanoma patients do not respond to immune checkpoint inhibitors (ICI), and until now, no validated biomarkers for response and survival have been known. Methods: We performed a retrospective analysis of outcomes in patients with metastatic melanoma treated with first-line ICI at the Institute of Oncology Ljubljana from January 2018 to December 2020. The immune-related adverse events (irAEs) and serum immune-inflammation parameters (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (LR), systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV)) were analyzed as potential biomarkers for response and survival. Survival rates were calculated using the Kaplan–Meier method and then compared with the log-rank test. Multivariate regression Cox analysis was used to determine independent prognostic factors for progression-free survival (PFS) and overall survival (OS). Results: Median follow-up was 22.5 months. The estimated median progression-free survival (PFS) was 15 months (95% CI 3.3–26.2). The two-year survival rate (OS) was 66.6%. Among 129 treated patients, 24 (18.6%) achieved complete response, 28 (21.7%) achieved partial response, 26 (20.2%) had stable disease and 51 (39.5%) patients experienced a progressive disease. There was a higher response rate in patients with irAEs (p < 0.001) and high NLR before the second cycle of ICI (p = 0.052). Independent prognostic factors for PFS were irAE (HR 0.41 (95% CI 0.23–0.71)), SII before the first cycle of ICI (HR 1.94 (95% CI 1.09–3.45)) and PLR before the second cycle of ICI (HR 1.71 (95% CI 1.03–2.83)). The only independent prognostic factor for OS was SII before the first cycle of ICI (HR 2.60 (95% CI 0.91–7.50)). Conclusions: Patients with high pre-treatment levels of SII had a higher risk of progression and death; however, patients with irAEs in the high-SII group might respond well to ICI. Patients who develop irAEs and have high NLRs before the second ICI application have higher rates of CR and PR, which implicates their use as early biomarkers for responsiveness to ICI.

[1]  T. Gambichler,et al.  The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy , 2022, Journal of Cancer Research and Clinical Oncology.

[2]  M. Del Vecchio,et al.  The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy , 2021, Targeted Oncology.

[3]  J. Theysohn,et al.  Predictive Impact of The Inflammation-based Indices in Uveal Melanoma Liver Metastases Treated with Transarterial Hepatic Chemoperfusion , 2021, Radiology and oncology.

[4]  Li Zhou,et al.  Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials , 2021, Frontiers in Oncology.

[5]  T. Mesti,et al.  Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes , 2021, Radiology and oncology.

[6]  M. Fassan,et al.  The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. , 2021, European journal of cancer.

[7]  Zhuoli Zhang,et al.  Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis , 2021, Frontiers in Oncology.

[8]  G. Mariani,et al.  The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab , 2021, Cancers.

[9]  S. Tirumani,et al.  Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors , 2021, JAMA network open.

[10]  Xiao-yan Li,et al.  Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade , 2021, Frontiers in Oncology.

[11]  O. Dizdar,et al.  PILE: a candidate prognostic score in cancer patients treated with immunotherapy , 2021, Clinical and Translational Oncology.

[12]  R. Dummer,et al.  Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma , 2020, European journal of cancer.

[13]  D. Bodet,et al.  Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients , 2020, Clinical and Translational Oncology.

[14]  V. Adamo,et al.  The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials , 2020, British Journal of Cancer.

[15]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[16]  C. Keeble,et al.  The neutrophil–lymphocyte ratio and locoregional melanoma: a multicentre cohort study , 2020, Cancer Immunology, Immunotherapy.

[17]  T. Mesti,et al.  Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience , 2020, Radiology and oncology.

[18]  D. Schadendorf,et al.  Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.

[19]  P. Ascierto,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Lei Zhan,et al.  How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. , 2019, American journal of cancer research.

[21]  J. Larkin,et al.  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. , 2019, The Lancet. Oncology.

[22]  C. Mirili,et al.  Clinical significance of prognostic nutritional index (PNI) in malignant melanoma , 2019, International Journal of Clinical Oncology.

[23]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[25]  J. Cebon,et al.  Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma , 2018, Journal of surgical oncology.

[26]  Wan-Hai Wang,et al.  Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis , 2018, Journal of Cancer.

[27]  M. Marples,et al.  Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study , 2018, Annals of Surgical Oncology.

[28]  P. Queirolo,et al.  Current status and perspectives in immunotherapy for metastatic melanoma , 2015, Oncotarget.

[29]  C. Cui,et al.  Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon , 2017, Translational oncology.

[30]  Zi-Yu Chen,et al.  Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis , 2017, Oncotarget.

[31]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[32]  E. Scarpi,et al.  Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer , 2016, Oncotarget.

[33]  H. Muss,et al.  Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis. , 2015, Cancer treatment reviews.

[34]  B. Zhou,et al.  Inflammation fuels tumor progress and metastasis. , 2015, Current pharmaceutical design.

[35]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  I. Tannock,et al.  Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[37]  Berthold Lausen,et al.  Maximally selected rank statistics , 1992 .